Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program

BACKGROUND: Circulating tumor cells (CTCs) have been reported to predict clinical outcome in metastatic breast cancer (MBC). Biology of CTCs may differ from that of the primary tumor and HER2-positive CTCs are found in some patients with HER2-negative tumors. PATIENTS AND METHODS: Patients with HER2...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, V., Banys-Paluchowski, M., Friedl, T.W.P., Fasching, P.A., Schneeweiss, A., Hartkopf, A., Wallwiener, D., Rack, B., Meier-Stiegen, F., Huober, J., Rübner, M., Hoffmann, O., Müller, L., Janni, W., Wimberger, P., Jäger, B., Pantel, K., Riethdorf, S., Harbeck, N., Fehm, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637493/
https://www.ncbi.nlm.nih.gov/pubmed/34839105
http://dx.doi.org/10.1016/j.esmoop.2021.100299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637493/
https://www.ncbi.nlm.nih.gov/pubmed/34839105
http://dx.doi.org/10.1016/j.esmoop.2021.100299

Ejemplares similares